Iterum Therapeutics(ITRM) - 2024 Q3 - Quarterly Results

EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Third Quarter 2024 Financial Results -- ORLYNVAHTM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN, Ireland and CHICAGO, November 14, 2024 -- Iterum Therapeutics plc (Nasdaq: ITRM), (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial res ...